Experience Recombinant Hepatitis B Virus (hbv)(ayw/france/tiollais/1979) Capsid Protein (his Tag) 65% Off - Today Only [OkIHFYml]

Recombinant Hepatitis B Virus Capsid Protein (His Tag)

The Experience Recombinant Hepatitis B Virus (hbv)(ayw/france/tiollais/1979) Capsid Protein (his Tag) 65% Off - Today Only [OkIHFYml] is a high-quality recombinant protein derived from the HBV capsid. This protein is produced in E. coli and is tagged with a His Tag for easy purification. With a calculated molecular weight of 17.7 kDa and a purity of >95%, this protein is ideal for a variety of research applications. Its specific sequence Met1-Val149 and Accession P03146-1 make it a valuable tool for understanding the structure and function of the HBV capsid.

Key Features and Specifications

This recombinant protein is expressed in E. coli, ensuring high yield and purity. The His Tag facilitates purification and detection, making it easier to work with. The protein is lyophilized from a sterile solution containing 150mM NaCl, 50mM Tris, 0.5mM EDTA, pH 7.0, with additional protectants such as trehalose, mannitol, and Tween 80 for stability. It is shipped with ice packs to maintain its integrity during transportation. The protein is not validated for activity, but its high purity and specificity make it a valuable resource for researchers studying HBV capsid assembly and related processes.

Applications and Benefits

The Recombinant Hepatitis B Virus Capsid protein (His Tag) is an essential tool for researchers studying HBV and its capsid assembly. Its high purity and specificity make it ideal for use in various applications, including antibody production, enzyme-linked immunosorbent assays (ELISAs), and protein-protein interaction studies. The protein's ease of purification and detection, combined with its stability and shipping convenience, make it a cost-effective and practical choice for researchers in virology, immunology, and infectious diseases. With this product, you can advance your research on HBV capsid assembly and contribute to the development of new antiviral therapies.